The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation.
The prognostic significance of eosinophilia after myeloablative allogeneic stem cell transplantation (ASCT) remains to be established. Patients, whom developed chronic graft-versus-host disease (cGVHD) after ASCT, were included (n = 142). Eosinophil count was analyzed at cGVHD onset. We observed no significant association between EO and the grade of cGVHD, thrombocytopenia, nor extensive skin involvement. Importantly, we observed no significant association between cGVHD with concomitant eosinophilia and long-term clinical outcomes, and subgroup analyses revealed a considerable confounding effect of ongoing steroid treatment. In conclusion, we advocate that prognostic conclusions regarding cGVHD with concomitant eosinophilia after ASCT should be interpreted with caution.
Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: katrinekbm@gmail.com.
Katrine Brandt
KB
Mortensen
Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
Thomas Alexander
TA
Gerds
Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
Ole Weis
OW
Bjerrum
Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
Anders
A
Lindmark
Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
Henrik
H
Sengeløv
Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark; Department of Hematology, Roskilde Hospital, Roskilde, Denmark.
Christen Lykkegaard
CL
Andersen
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000473:pathology; D004802:Eosinophilia / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D004804:Eosinophils / Q000473:pathology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D012867:Skin / Q000473:pathology; D014184:Transplantation, Homologous
D005938:Glucocorticoids; D019653:Myeloablative Agonists
Allogeneic stem cell transplantation; Chronic graft-versus-host disease; Clinical outcome; Eosinophilia; Glucocorticoids; Myeloablative